CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Harmony Biosciences Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Harmony Biosciences Holdings Inc
630 W Germantown Pike, Suite 215
Phone: (484) 539-9800p:484 539-9800 PLYMOUTH MEETING, PA  19462  United States Ticker: HRMYHRMY
Business Summary
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. It is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Jeffrey S.Aronin 56 4/24/2023 10/1/2017
President, Chief Executive Officer, Director Jeffrey M.Dayno 66 4/24/2023 11/1/2017
Chief Financial Officer, Chief Administrative Officer Sandip S.Kapadia 54 9/30/2023 3/1/2021
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Zynerba Pharmaceuticals Inc 80 W. Lancaster Avenue, Suite 300 DEVON PA United States

Business Names
Business Name
Epygenix Therapeutics, Inc.
Harmony Biosciences, LLC
HRMY
Zynerba Pharmaceuticals Inc
Zynerba Pharmaceuticals Pty Ltd
Zynerba Pharmaceuticals, Inc.

General Information
Number of Employees: 246 (As of 12/31/2023)
Outstanding Shares: 57,031,297 (As of 10/25/2024)
Shareholders: 35
Stock Exchange: NASD
Federal Tax Id: 822279923
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024